;PMID: 9189100
;source_file_1407.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..112] = [t:36..112]
;2)section:[e:116..202] = [t:116..202]
;3)section:[e:206..268] = [t:206..268]
;4)sentence:[e:272..283] = [t:272..283]
;5)sentence:[e:284..493] = [t:284..493]
;6)sentence:[e:494..502] = [t:494..502]
;7)sentence:[e:504..797] = [t:504..797]
;8)sentence:[e:798..806] = [t:798..806]
;9)sentence:[e:807..931] = [t:807..931]
;10)sentence:[e:932..1162] = [t:932..1162]
;11)sentence:[e:1163..1294] = [t:1163..1294]
;12)sentence:[e:1295..1306] = [t:1295..1306]
;13)sentence:[e:1307..1380] = [t:1307..1380]
;14)sentence:[e:1381..1461] = [t:1381..1461]
;15)section:[e:1465..1509] = [t:1465..1509]

;section 0 Span:0..31
;Br J Surg  1997 Jun;84(6):826-9
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..9] Surg) (CD:[11..15] 1997)
        (.:[16..23] Jun;84-LRB-) (CD:[23..25] 6-RRB-) (CD:[25..29] :826)
        (HYPH:[29..30] -) (CD:[30..31] 9)))

;sentence 1 Span:36..112
;p53 and K-ras status in duodenal adenomas in familial adenomatous polyposis.
;[36..39]:gene-rna:"p53"
;[44..49]:gene-rna:"K-ras"
;[60..77]:malignancy:"duodenal adenomas"
;[81..111]:malignancy:"familial adenomatous polyposis"
(SENT
  (NP-HLN
    (NP
      (NML (NN:[36..39] p53) (CC:[40..43] and) (NN:[44..49] K-ras))
      (NN:[50..56] status))
    (PP (IN:[57..59] in)
      (NP (JJ:[60..68] duodenal) (NNS:[69..77] adenomas)))
    (PP (IN:[78..80] in)
      (NP (JJ:[81..89] familial) (JJ:[90..101] adenomatous)
          (NN:[102..111] polyposis)))
    (.:[111..112] .)))

;section 2 Span:116..202
;Kashiwagi H, Spigelman AD, Talbot IC, Debinski HS, McKie AB, Lemoine NR, 
;Phillips RK.
(SEC
  (FRAG (NNP:[116..125] Kashiwagi) (NNP:[126..127] H) (,:[127..128] ,)
        (NNP:[129..138] Spigelman) (NNP:[139..141] AD) (,:[141..142] ,)
        (NNP:[143..149] Talbot) (NNP:[150..152] IC) (,:[152..153] ,)
        (NNP:[154..162] Debinski) (NNP:[163..165] HS) (,:[165..166] ,)
        (NNP:[167..172] McKie) (NNP:[173..175] AB) (,:[175..176] ,)
        (NNP:[177..184] Lemoine) (NNP:[185..187] NR) (,:[187..188] ,)
        (NNP:[190..198] Phillips) (NNP:[199..202] RK.)))

;section 3 Span:206..268
;Polyposis Registry, St Mark's Hospital, Harrow, Middlesex, UK.
(SEC
  (FRAG (NNP:[206..215] Polyposis) (NNP:[216..224] Registry) (,:[224..225] ,)
        (NNP:[226..228] St) (NNP:[229..233] Mark) (POS:[233..235] 's)
        (NNP:[236..244] Hospital) (,:[244..245] ,) (NNP:[246..252] Harrow)
        (,:[252..253] ,) (NNP:[254..263] Middlesex) (,:[263..264] ,)
        (NNP:[265..268] UK.)))

;sentence 4 Span:272..283
;BACKGROUND:
(SENT
  (NP (NN:[272..282] BACKGROUND) (::[282..283] :)))

;sentence 5 Span:284..493
;The genetic alterations in patients with familial adenomatous  polyposis
;(FAP) and duodenal adenomas are poorly characterized when compared  with data
;relating to colorectal tumorigenesis in the same patients.
;[325..356]:malignancy:"familial adenomatous  polyposis"
;[358..361]:malignancy:"FAP"
;[367..384]:malignancy:"duodenal adenomas"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[284..287] The) (JJ:[288..295] genetic)
          (NNS:[296..307] alterations))
      (PP-LOC (IN:[308..310] in)
        (NP
          (NP (NNS:[311..319] patients))
          (PP (IN:[320..324] with)
            (NP
              (NP
                (NP (JJ:[325..333] familial) (JJ:[334..345] adenomatous)
                    (NN:[347..356] polyposis))
                (NP (-LRB-:[357..358] -LRB-) (NN:[358..361] FAP)
                    (-RRB-:[361..362] -RRB-)))
              (CC:[363..366] and)
              (NP (JJ:[367..375] duodenal) (NNS:[376..384] adenomas)))))))
    (VP (VBP:[385..388] are)
      (ADJP-PRD (RB:[389..395] poorly) (VBN:[396..409] characterized)
        (SBAR-ADV (WRB:[410..414] when)
          (S
            (NP-SBJ-1 (-NONE-:[414..414] *))
            (VP (VBN:[415..423] compared)
              (NP-1 (-NONE-:[423..423] *))
              (PP-CLR (IN:[425..429] with)
                (NP
                  (NP (NNS:[430..434] data))
                  (VP (VBG:[435..443] relating)
                    (PP-CLR (TO:[444..446] to)
                      (NP
                        (NP (JJ:[447..457] colorectal)
                            (NN:[458..471] tumorigenesis))
                        (PP-LOC (IN:[472..474] in)
                          (NP (DT:[475..478] the) (JJ:[479..483] same)
                              (NNS:[484..492] patients)))))))))))))
    (.:[492..493] .)))

;sentence 6 Span:494..502
;METHODS:
(SENT
  (NP (NNS:[494..501] METHODS) (::[501..502] :)))

;sentence 7 Span:504..797
;Point mutation of the K-ras oncogene and point mutation and overexpression of
; the TP53 tumour suppressor gene were investigated in 32 duodenal polyps
;(seven  without mucosal pathology, 23 with mildly dysplastic adenomas and two
;with  moderately dysplastic adenomas) from 21 patients with FAP.
;[504..518]:variation-type:"Point mutation"
;[526..531]:gene-rna:"K-ras"
;[545..559]:variation-type:"point mutation"
;[587..591]:gene-rna:"TP53"
;[639..654]:malignancy:"duodenal polyps"
;[705..724]:malignancy:"dysplastic adenomas"
;[750..769]:malignancy:"dysplastic adenomas"
;[793..796]:malignancy:"FAP"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (NN:[504..509] Point) (NN:[510..518] mutation))
        (PP (IN:[519..521] of)
          (NP (DT:[522..525] the) (NN:[526..531] K-ras) (NN:[532..540] oncogene))))
      (CC:[541..544] and)
      (NP
        (NP
          (NP (NN:[545..550] point) (NN:[551..559] mutation))
          (CC:[560..563] and)
          (NP (NN:[564..578] overexpression)))
        (PP (IN:[579..581] of)
          (NP (DT:[583..586] the) (NN:[587..591] TP53)
            (NML (NN:[592..598] tumour) (NN:[599..609] suppressor))
            (NN:[610..614] gene)))))
    (VP (VBD:[615..619] were)
      (VP (VBN:[620..632] investigated)
        (NP-1 (-NONE-:[632..632] *))
        (PP-LOC (IN:[633..635] in)
          (NP
            (NP (CD:[636..638] 32)
               (JJ:[639..647] duodenal) (NNS:[648..654] polyps)
              (PRN (-LRB-:[655..656] -LRB-)
                (NP
                  (NP
                    (NP (CD:[656..661] seven))
                    (PP (IN:[663..670] without)
                      (NP (JJ:[671..678] mucosal) (NN:[679..688] pathology))))
                  (,:[688..689] ,)
                  (NP
                    (NP (CD:[690..692] 23))
                    (PP (IN:[693..697] with)
                      (NP
                        (ADJP (RB:[698..704] mildly) (JJ:[705..715] dysplastic))
                        (NNS:[716..724] adenomas))))
                  (CC:[725..728] and)
                  (NP
                    (NP (CD:[729..732] two))
                    (PP (IN:[733..737] with)
                      (NP
                        (ADJP (RB:[739..749] moderately)
                              (JJ:[750..760] dysplastic))
                        (NNS:[761..769] adenomas)))))
                (-RRB-:[769..770] -RRB-)))
            (PP (IN:[771..775] from)
              (NP
                (NP (CD:[776..778] 21) (NNS:[779..787] patients))
                (PP (IN:[788..792] with)
                  (NP (NN:[793..796] FAP)))))))))
    (.:[796..797] .)))

;sentence 8 Span:798..806
;RESULTS:
(SENT
  (NP (NNS:[798..805] RESULTS) (::[805..806] :)))

;sentence 9 Span:807..931
;K-ras  mutation, TP53 mutation or positive p53 staining were not found in
;duodenal  polyps without histological abnormality.
;[807..812]:gene-rna:"K-ras"
;[824..828]:gene-rna:"TP53"
;[850..853]:gene-protein:"p53"
;[881..897]:malignancy:"duodenal  polyps"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[807..812] K-ras) (NN:[814..822] mutation))
      (,:[822..823] ,)
      (NP (NN:[824..828] TP53) (NN:[829..837] mutation))
      (CC:[838..840] or)
      (NP (JJ:[841..849] positive) (NN:[850..853] p53) (NN:[854..862] staining)))
    (VP (VBD:[863..867] were) (RB:[868..871] not)
      (VP (VBN:[872..877] found)
        (NP-1 (-NONE-:[877..877] *))
        (PP-LOC (IN:[878..880] in)
          (NP
            (NP (JJ:[881..889] duodenal) (NNS:[891..897] polyps))
            (PP (IN:[898..905] without)
              (NP (JJ:[906..918] histological) (NN:[919..930] abnormality)))))))
    (.:[930..931] .)))

;sentence 10 Span:932..1162
;Of 25 duodenal adenomas, K-ras mutation  was found in three (two mildly
;dysplastic, one moderately dysplastic), 20 showed  positive p53
;immunostaining, and mutation of the TP53 gene was found in one  moderately
;dysplastic adenoma.
;[938..955]:malignancy:"duodenal adenomas"
;[957..962]:gene-rna:"K-ras"
;[1004..1014]:malignancy:"dysplastic"
;[1031..1041]:malignancy:"dysplastic"
;[1064..1067]:gene-protein:"p53"
;[1104..1108]:gene-rna:"TP53"
;[1143..1161]:malignancy:"dysplastic adenoma"
(SENT
  (S
    (S
      (PP-2 (IN:[932..934] Of)
        (NP (CD:[935..937] 25)
           (JJ:[938..946] duodenal) (NNS:[947..955] adenomas)))
      (,:[955..956] ,)
      (NP-SBJ-3 (NN:[957..962] K-ras) (NN:[963..971] mutation))
      (VP (VBD:[973..976] was)
        (VP (VBN:[977..982] found)
          (NP-3 (-NONE-:[982..982] *))
          (PP-LOC (IN:[983..985] in)
            (NP
              (NP (CD:[986..991] three)
                (PRN (-LRB-:[992..993] -LRB-) (CD:[993..996] two)
                  (ADJP (RB:[997..1003] mildly) (JJ:[1004..1014] dysplastic))
                  (,:[1014..1015] ,)
                  (NP (CD:[1016..1019] one)
                    (ADJP (RB:[1020..1030] moderately)
                          (JJ:[1031..1041] dysplastic)))
                  (-RRB-:[1041..1042] -RRB-)))
              (PP-2 (-NONE-:[1042..1042] *T*)))))))
    (,:[1042..1043] ,)
    (S
      (NP-SBJ (CD:[1044..1046] 20))
      (VP (VBD:[1047..1053] showed)
        (NP (JJ:[1055..1063] positive) (NN:[1064..1067] p53)
            (NN:[1068..1082] immunostaining))))
    (,:[1082..1083] ,) (CC:[1084..1087] and)
    (S
      (NP-SBJ-1
        (NP (NN:[1088..1096] mutation))
        (PP (IN:[1097..1099] of)
          (NP (DT:[1100..1103] the) (NN:[1104..1108] TP53)
              (NN:[1109..1113] gene))))
      (VP (VBD:[1114..1117] was)
        (VP (VBN:[1118..1123] found)
          (NP-1 (-NONE-:[1123..1123] *))
          (PP-LOC (IN:[1124..1126] in)
            (NP (CD:[1127..1130] one)
              (ADJP (RB:[1132..1142] moderately) (JJ:[1143..1153] dysplastic))
              (NN:[1154..1161] adenoma))))))
    (.:[1161..1162] .)))

;sentence 11 Span:1163..1294
;p53 protein overexpression in duodenal adenomas  was significantly more
;frequent than mutation of either K-ras or TP53 (P <  0.01).
;[1163..1166]:gene-protein:"p53"
;[1193..1210]:malignancy:"duodenal adenomas"
;[1268..1273]:gene-rna:"K-ras"
;[1277..1281]:gene-rna:"TP53"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1163..1166] p53) (NN:[1167..1174] protein)
          (NN:[1175..1189] overexpression))
      (PP-LOC (IN:[1190..1192] in)
        (NP (JJ:[1193..1201] duodenal) (NNS:[1202..1210] adenomas))))
    (VP (VBD:[1212..1215] was)
      (ADJP-PRD
        (ADJP
          (ADVP (RB:[1216..1229] significantly) (RBR:[1230..1234] more))
          (JJ:[1235..1243] frequent))
        (PP (IN:[1244..1248] than)
          (NP
            (NP (NN:[1249..1257] mutation))
            (PP (IN:[1258..1260] of)
              (NP (CC:[1261..1267] either) (NN:[1268..1273] K-ras)
                  (CC:[1274..1276] or) (NN:[1277..1281] TP53))))))
      (PRN (-LRB-:[1282..1283] -LRB-)
        (S
          (NP-SBJ (NN:[1283..1284] P))
          (VP (SYM:[1285..1286] <)
            (NP (CD:[1288..1292] 0.01))))
        (-RRB-:[1292..1293] -RRB-)))
    (.:[1293..1294] .)))

;sentence 12 Span:1295..1306
;CONCLUSION:
(SENT
  (NP (NN:[1295..1305] CONCLUSION) (::[1305..1306] :)))

;sentence 13 Span:1307..1380
;p53 dysfunction is a hallmark of duodenal adenomas in  patients with FAP.
;[1307..1310]:gene-generic:"p53"
;[1340..1357]:malignancy:"duodenal adenomas"
;[1376..1379]:malignancy:"FAP"
(SENT
  (S
    (NP-SBJ (NN:[1307..1310] p53) (NN:[1311..1322] dysfunction))
    (VP (VBZ:[1323..1325] is)
      (NP
        (NP (DT:[1326..1327] a) (NN:[1328..1336] hallmark))
        (PP (IN:[1337..1339] of)
          (NP (JJ:[1340..1348] duodenal) (NNS:[1349..1357] adenomas))))
      (PP-LOC (IN:[1358..1360] in)
        (NP
          (NP (NNS:[1362..1370] patients))
          (PP (IN:[1371..1375] with)
            (NP (NN:[1376..1379] FAP))))))
    (.:[1379..1380] .)))

;sentence 14 Span:1381..1461
;Overexpression may indicate DNA damage and thus an early step  in
;tumorigenesis.
(SENT
  (S
    (NP-SBJ (NN:[1381..1395] Overexpression))
    (VP (MD:[1396..1399] may)
      (VP (VB:[1400..1408] indicate)
        (NP
          (NP (NN:[1409..1412] DNA) (NN:[1413..1419] damage))
          (CONJP (CC:[1420..1423] and) (RB:[1424..1428] thus))
          (NP
            (NP (DT:[1429..1431] an) (JJ:[1432..1437] early)
                (NN:[1438..1442] step))
            (PP (IN:[1444..1446] in)
              (NP (NN:[1447..1460] tumorigenesis)))))))
    (.:[1460..1461] .)))

;section 15 Span:1465..1509
;PMID: 9189100 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1465..1469] PMID) (::[1469..1470] :) (CD:[1471..1478] 9189100)
        (IN:[1479..1480] -LSB-) (NNP:[1480..1486] PubMed) (HYPH:[1487..1488] -)
        (JJ:[1489..1496] indexed) (IN:[1497..1500] for)
        (NNP:[1501..1509] MEDLINE-RSB-)))
